Comparison of Opioid Doctor Shopping for Tapentadol and Oxycodone: A Cohort Study |
| |
Authors: | M. Soledad Cepeda Daniel Fife Lien Vo Gregory Mastrogiovanni Yingli Yuan |
| |
Affiliation: | 1. Janssen Pharmaceutical Research & Development, LLC, Titusville, New Jersey;2. Janssen Scientific Affairs, LLC, Titusville, New Jersey;3. IMS Health, Collegeville, Pennsylvania |
| |
Abstract: | Obtaining opioids from multiple prescribers, known as doctor shopping, is 1 example of opioid abuse and diversion. The dual mechanism of action of tapentadol could make tapentadol less likely to be abused than other opioids. The aim of this retrospective cohort study was to compare the risk of shopping behavior between tapentadol immediate release (IR) and oxycodone IR. Subjects exposed to tapentadol or oxycodone with no recent opioid use were included and followed for 1 year. The primary outcome was the proportion of subjects who developed shopping behavior defined as subjects who had opioid prescriptions written by >1 prescriber with ≥1 day of overlap filled at ≥3 pharmacies. The opioids involved in the shopping episodes were assessed. A total of 112,821 subjects were exposed to oxycodone and 42,940 to tapentadol. Shopping behavior was seen in .8% of the subjects in the oxycodone group and in .2% of the subjects in the tapentadol group, for an adjusted odds ratio of 3.5 (95% confidence interval, 2.8 to 4.4). In the oxycodone group, 28.0% of the shopping events involved exclusively oxycodone, whereas in the tapentadol group, .6% of the shopping events involved exclusively tapentadol. Results suggest that the risk of shopping behavior is substantially lower with tapentadol than with oxycodone.PerspectiveThe risk of opioid doctor shopping, ie, obtaining opioid prescriptions from multiple prescribers, is lower with tapentadol than with oxycodone. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|